Orbus Therapeutics Inc., a private, clinical-stage biopharmaceutical company is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The Company's product candidate in clinical development is eflornithine. Eflornithine is a novel cytostatic agent, which the Company is developing to treat patients with recurrent anaplastic astrocytoma (rAA), a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in certain types of cancer.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/20/15 | $32,500,000 | Series A |
Adams Street Partners Ernest Mario H.I.G. BioVentures Longitude Capital | undisclosed |
